Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

Trial Profile

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs AB SA01 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 05 Dec 2016 Results published in an AmpliPhi Biosciences Corporation media release.
    • 13 Sep 2016 AmpliPhi expects to report final results of the trial by the end of 2016, according to a company media release.
    • 13 Sep 2016 Topline results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top